Overview

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
0
Participant gender:
All
Summary
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Candesartan
Candesartan cilexetil
Criteria
Inclusion Criteria:

- Male or female aged 18 or above

- Congestive Heart Failure with symptoms for more than 4 weeks before starting study

- Provision of informed consent

Exclusion Criteria:

- Current low blood pressure with symptoms

- Liver disease considered significant by the study doctor

- Pregnant or lactating females